Cargando…

Survey of experts on therapeutic policies and proposals for the optimal timing for allogeneic peripheral blood stem cell transplantation in transfusion-dependent patients with myelodysplastic syndrome-refractory anemia

BACKGROUND: Most hypomethylating agent (HMA) responders with myelodysplastic syndrome (MDS) eventually need allogeneic stem cell transplantation (SCT) because they often acquire resistance to HMAs within two years of treatment. Considering the nature of MDS and the poor outcomes of SCT when performe...

Descripción completa

Detalles Bibliográficos
Autores principales:	Sohn, Sang Kyun, Moon, Joon Ho, Lee, Yoo Jin, Park, Sung Woo, Kim, Ji Yoon
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Korean Society of Hematology; Korean Society of Blood and Marrow Transplantation; Korean Society of Pediatric Hematology-Oncology; Korean Society on Thrombosis and Hemostasis 2016
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4828528/ https://www.ncbi.nlm.nih.gov/pubmed/27104191 http://dx.doi.org/10.5045/br.2016.51.1.44

Ejemplares similares

PB2011: TRANSFUSION BURDEN IS AN IMPORTANT PROGNOSTIC FACTOR IN LOWER-RISK MYELODYSPLASTIC SYNDROME
por: Lee, Jungmin, et al.
Publicado: (2023)

Plasma proteome changes associated with refractory anemia and refractory anemia with ringed sideroblasts in patients with myelodysplastic syndrome
por: Májek, Pavel, et al.
Publicado: (2013)

Cardiac iron overload in chronically transfused patients with thalassemia, sickle cell anemia, or myelodysplastic syndrome
por: de Montalembert, Mariane, et al.
Publicado: (2017)

Successful allogeneic bone marrow transplantation for childhood-onset refractory anemia with ringed sideroblasts.
por: Kook, H., et al.
Publicado: (2000)

Bullous Pemphigoid in an Elderly Patient with Myelodysplastic Syndrome and Refractory Anemia Coupled with Excess of Blast
por: Lee, Yin Yin, et al.
Publicado: (2011)

Cardiac and hepatic siderosis in myelodysplastic syndrome, thalassemia and diverse causes of transfusion-dependent anemia: the TIMES study
por: Ho, P. Joy, et al.
Publicado: (2019)

How do I/We forecast tomorrow’s transfusion? A series of experts’ proposals for changes in transfusion medicine
por: Garraud, Olivier, et al.
Publicado: (2022)

Proteome Changes in the Plasma of Myelodysplastic Syndrome Patients with Refractory Anemia with Excess Blasts Subtype 2
por: Majek, Pavel, et al.
Publicado: (2014)

Evolution of chronic myelomonocytic leukemia from refractory anemia: the unusual course of a myelodysplastic syndrome
por: Niscola, Pasquale, et al.
Publicado: (2013)

Plasma protein alterations in the refractory anemia with excess blasts subtype 1 subgroup of myelodysplastic syndrome
por: Májek, Pavel, et al.
Publicado: (2012)

Clinical outcomes of transfusion-associated iron overload in patients with refractory chronic anemia
por: Gao, Chong, et al.
Publicado: (2014)

JAK2 V617F mutation in myelodysplastic syndrome, myelodysplastic syndrome/myeloproliferative neoplasm, unclassifiable, refractory anemia with ring sideroblasts with thrombocytosis, and acute myeloid leukemia
por: Jekarl, Dong Wook, et al.
Publicado: (2010)

Donor Cell-Derived Myelodysplastic Syndrome Following Allogenic Peripheral Blood Stem Cell Transplant
por: Narang, Ujjwala, et al.
Publicado: (2023)

Identification of genes underlying different methylation profiles in refractory anemia with excess blast and refractory cytopenia with multilineage dysplasia in myelodysplastic syndrome
por: Lee, Suee, et al.
Publicado: (2012)

Myelodysplastic Syndrome with Transfusion Dependence Treated with Venetoclax
por: Jehangir, Waqas, et al.
Publicado: (2020)

Five‐day regimen of azacitidine for lower‐risk myelodysplastic syndromes (refractory anemia or refractory anemia with ringed sideroblasts): A prospective single‐arm phase 2 trial
por: Morita, Yasuyoshi, et al.
Publicado: (2018)

Results of Multicenter Phase II Study With Imatinib Mesylate in Allogeneic Recipients With Steroid-Refractory Chronic GVHD
por: Baek, Dong Won, et al.
Publicado: (2022)

Anemia and RBC Transfusion
por: Marik, Paul Ellis
Publicado: (2009)

A case of anemia: How important is peripheral blood film before transfusing?
por: Kumar, Pankaj, et al.
Publicado: (2017)

Glutathione promotes the synergistic effects of venetoclax and azacytidine against myelodysplastic syndrome‑refractory anemia by regulating the cell cycle
por: Wang, Xiaobo, et al.
Publicado: (2023)

New synergistic efficacy of combination of romiplostim and steroid in refractory immune thrombocytopenia patients
por: Yoon, Jun Seok, et al.
Publicado: (2018)

Lichen Striatus Occurring after Allogenic Peripheral Blood Stem Cell Transplantation in an Adult with Aplastic Anemia
por: Mun, Je-Ho, et al.
Publicado: (2012)

Proposed public policies to improve outcomes in vascular surgery: an experts’ forum
por: Wolosker, Nelson, et al.
Publicado: (2023)

Spur Cells Causing Severe and Transfusion-Refractory Anemia in Patients With Acute-on-Chronic Liver Failure
por: Kedarisetty, Chandan kumar, et al.
Publicado: (2020)

Ferric Carboxymaltose and Erythropoiesis-Stimulating Agent Treatment Reduces the Rate of Blood Transfusion in Refractory Anemia
por: Gidaro, Antonio, et al.
Publicado: (2022)

Effect of severity and cause of preoperative anemia on the transfusion rate after total knee arthroplasty
por: Kim, Tae Woo, et al.
Publicado: (2022)

Reduced-Intensity Allogeneic Stem Cell Transplantation for Co-Emergence of Chemotherapy-Refractory Follicular Lymphoma and Therapy-Related Myelodysplastic Syndrome
por: Shimura, Yuji, et al.
Publicado: (2014)

Anemia and transfusion therapy: an update
por: Madrazo-González, Z., et al.
Publicado: (2011)

Severe atypical herpes zoster as an initial symptom of fatal myelodysplastic syndrome with refractory anemia and blast excess (RAEB II)
por: Wollina, Uwe, et al.
Publicado: (2017)

Outcome in hip fracture patients related to anemia at admission and allogeneic blood transfusion: an analysis of 1262 surgically treated patients
por: Vochteloo, Anne JH, et al.
Publicado: (2011)

Transfusion Thresholds, Quality of Life, and Current Approaches in Myelodysplastic Syndromes
por: Koutsavlis, Ioannis
Publicado: (2016)

No benefit of hypomethylating agents compared to supportive care for higher risk myelodysplastic syndrome
por: Sohn, Sang Kyun, et al.
Publicado: (2018)

Resolution of alloimmunization and refractory autoimmune hemolytic anemia in a multi-transfused beta-thalassemia major patient
por: Philip, Joseph, et al.
Publicado: (2014)

Clinical Effects of Hypomethylating Agents in Patients with Newly Diagnosed Myelodysplastic Syndrome Who Received DNA-Damaging Chemotherapy for Metastatic Breast Cancer
por: Baek, Dong Won, et al.
Publicado: (2019)

Management of refractory autoimmune hemolytic anemia after allogeneic hematopoietic stem cell transplantation: current perspectives
por: Barcellini, Wilma, et al.
Publicado: (2019)

Megaloblastic Anemia with Ring Sideroblasts is not Always Myelodysplastic Syndrome
por: Narang, Neha Chopra, et al.
Publicado: (2016)

Pernicious anemia: a myelodysplastic syndrome look-alike
por: Kesbeh, Yazeed, et al.
Publicado: (2019)

Restrictive allogeneic blood transfusion strategy in patients with extremity bone sarcomas
por: Park, Jong Hoon, et al.
Publicado: (2019)

Does Autologous Transfusion Decrease Allogeneic Transfusion in Liposuction Surgery of Lymphedema Patients?
por: Chen, Linfeng, et al.
Publicado: (2022)

The Use of Splenectomy to Manage Platelet Transfusion Refractoriness due to Anti-Human Leukocyte Antibodies in Allogeneic Stem Cell Transplantation
por: Mauro, Margherita, et al.
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_ahnulq32bd8q2o384ttjc6buol